CALT - Calliditas Therapeutics AB (publ)
NASDAQ
->
Healthcare
->
Biotechnology
Stockholm,
Sweden
Type: Equity
CALT price evolution
CALT
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $973.73 | $786.88 | $866.18 | $1013.6 |
| Short term investments | ||||
| Net receivables | $196.67 | $130.53 | $146.37 | $109.55 |
| Inventory | $20.43 | $16 | $17.7 | $12.16 |
| Total current assets | $1275.15 | $1036.01 | $1113.59 | $1219.71 |
| Long term investments | ||||
| Property, plant & equipment | $54.24 | $55.51 | $41.49 | $42.56 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1859.24 | $1611.89 | $1709.15 | $1788.72 |
| Current liabilities | ||||
| Accounts payable | $100.56 | $67.16 | $72.04 | $108 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $407.14 | $344.71 | $290.31 | $310.08 |
| Long term debt | $966.6 | $770.16 | $779.56 | $746.9 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1524.44 | $1259.46 | $1204.78 | $1199.31 |
| Shareholders' equity | ||||
| Retained earnings | ||||
| Other shareholder equity | $332.42 | $350.05 | $501.98 | $587.02 |
| Total shareholder equity | $334.81 | $352.44 | $504.37 | $589.4 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $973.73 | $1249.09 | $955.51 | $996.3 |
| Short term investments | ||||
| Net receivables | $196.67 | $88.72 | $11.34 | $22.8 |
| Inventory | $20.43 | $3.65 | $0.89 | |
| Total current assets | $1275.15 | $1412.2 | $1012.77 | $1036.85 |
| Long term investments | $0 | |||
| Property, plant & equipment | $54.24 | $31.92 | $39.61 | $5.41 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $51.19 | |||
| Total investments | ||||
| Total assets | $1859.24 | $1952.97 | $1459.91 | $1506.45 |
| Current liabilities | ||||
| Accounts payable | $100.56 | $160.4 | $67.97 | $53.83 |
| Deferred revenue | ||||
| Short long term debt | $10.37 | $9.59 | ||
| Total current liabilities | $407.14 | $325.23 | $135.45 | $105.62 |
| Long term debt | $966.6 | $728.82 | $189.16 | $0.88 |
| Total noncurrent liabilities | $15.75 | |||
| Total debt | ||||
| Total liabilities | $1524.44 | $1186.71 | $451.63 | $250.15 |
| Shareholders' equity | ||||
| Retained earnings | -$1827.01 | -$1418.35 | -$918.6 | |
| Other shareholder equity | $5.2 | $0 | -$35.2 | -$6.09 |
| Total shareholder equity | $334.81 | $766.26 | $1008.28 | $1210.49 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $451.56 | $294.59 | $191.35 | |
| Cost of revenue | $14.92 | $9.03 | ||
| Gross Profit | $429.26 | $279.67 | $182.32 | |
| Operating activities | ||||
| Research & development | $106.68 | $179.91 | $126.65 | |
| Selling, general & administrative | $293.17 | $259.17 | $239.77 | |
| Total operating expenses | $409.8 | $454.16 | $371.43 | |
| Operating income | -$159.57 | -$180.07 | ||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $4.11 | $4.28 | ||
| Interest expense | -$56.02 | -$4.51 | -$27.94 | |
| Net income | ||||
| Net income | -$18.37 | -$168.36 | -$187.52 | |
| Income (for common shares) | -$18.37 | -$168.36 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1206.89 | $802.88 | $229.35 | $0.87 |
| Cost of revenue | $60.46 | $15.2 | ||
| Gross Profit | $1146.42 | $787.68 | $229.35 | $0.87 |
| Operating activities | ||||
| Research & development | $502.22 | $414.75 | $357.49 | $241.37 |
| Selling, general & administrative | $1060.73 | $774.66 | $390.23 | $133.61 |
| Total operating expenses | $1579.94 | $1201.75 | $753.8 | $374.98 |
| Operating income | -$373.06 | -$398.87 | -$524.46 | -$374.1 |
| Income from continuing operations | ||||
| EBIT | -$524.46 | -$374.1 | ||
| Income tax expense | $9.17 | $2.85 | -$3.84 | $0.36 |
| Interest expense | -$83.96 | -$32.8 | -$0.39 | |
| Net income | ||||
| Net income | -$466.18 | -$412.27 | -$500.29 | -$433.49 |
| Income (for common shares) | -$466.18 | -$412.27 | -$500.29 | -$433.49 |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$168.36 | -$187.52 | ||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$62.53 | -$231.94 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$13.74 | -$7.42 | -$3.97 | -$2.91 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$2.89 | -$2.97 | ||
| Total cash flows from financing | $199.65 | -$2.89 | -$5.98 | -$2.97 |
| Effect of exchange rate | -$26.61 | $22.02 | ||
| Change in cash and equivalents | -$275.36 | -$79.3 | -$382.91 | -$235.49 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$466.18 | -$412.27 | -$500.29 | -$433.49 |
| Operating activities | ||||
| Depreciation | $12.91 | $2.82 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$434.66 | -$311.35 | -$461.59 | -$309.18 |
| Investing activities | ||||
| Capital expenditures | -$2.51 | |||
| Investments | -$0.01 | |||
| Total cash flows from investing | -$13.74 | -$5.14 | -$24.34 | -$172.61 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $95.12 | |||
| Net borrowings | $226.28 | $482.13 | $193.95 | -$3.97 |
| Total cash flows from financing | $199.65 | $575.99 | $435.16 | $768.56 |
| Effect of exchange rate | $39.51 | $9.97 | -$44.01 | |
| Change in cash and equivalents | -$275.36 | $293.59 | -$40.8 | $242.76 |
News
Fundamentals
| Market cap | $496.47M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 26.84M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 207.73 |
| Book/Share | 0.09 |
| Cash/Share | 36.28 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 4.55 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.13 |
| Quick ratio | 3.08 |